Table 3.
Efficacy outcomes
| Best overall response | All (N = 25) | Percent | 95% CI |
|---|---|---|---|
| CR | 3 | 12.0 | 2.6–31.2 |
| PR | 17 | 68.0 | 46.5–85.1 |
| LSD | 1 | 4.0 | 0.1–20.4 |
| SD | 1 | 4.0 | 0.1–20.4 |
| PD | 2 | 8.0 | 1.0–26.0 |
| NE | 1 | 4.0 | 0.1–20.4 |
| ORR (CR + PR) | 20 | 80.0 | 59.3–93.2 |
| CBR (CR + PR + LSD) | 21 | 84.0 | 63.9–95.5 |
| DCR (CR + PR + LSD + SD) | 22 | 88.0 | 68.8–97.5 |
CI confidence interval, CR complete response, PR partial response, LSD long-term stable disease ≥24 weeks, SD stable disease <24 weeks, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate, CBR clinical benefit rate